ÂÜÀòÂÒÂ×

Kevin Lai has held a variety of roles in the biotechnology industry since 2006. Kevin began their career as a Presidential Postdoctoral Fellow in Oncology Early Drug Discovery at Novartis Institutes for BioMedical Research. Kevin then moved to Fate Therapeutics as a Senior Scientist, where they managed the cell biology and assay development functions for pre-clinical programs. In 2010, they took on a consulting role at the Scripps Institution of Oceanography, where they investigated various business models and won first prize at the UC San Diego Triton Innovation Pitch Competition. Kevin then joined the Rady Venture Fund as a Due Diligence Team Member, and in 2012 they co-founded and became the Chief Financial Officer of ExCimex, a company specializing in the management of bed bugs in multi-unit residences. In 2016, they became Associate Director of Drug Discovery at Intercept Pharmaceuticals, where they built and led the in vitro biology function. In 2018, they joined Sigilon Therapeutics as Associate Director of CMC - Bioanalytical Assays, where they created the bioanalytical function and supported the advancement of Shielded Living Therapeutics. Most recently, in 2021, they became Director of Target Biology at Korro Bio, Inc.

Kevin Lai has a Ph.D. in Biology from the Massachusetts Institute of Technology (MIT), an MBA from the University of California, San Diego - Rady School of Management, additional coursework during their Ph.D. at the MIT Sloan School of Management in Strategic Decision Making in the Biomedical Business, and a B.S. in Biochemistry from Tufts University.